A method of manufacturing pharmaceutical antigen binding protein with high yield and minimum aggregation, wherein the antigen binding protein is an anti-Dengue monoclonal antibody according to SEQ ID 1 and SEQ ID 2 or wherein the antigen binding protein is an anti-Rabies monoclonal antibody according to SEQ ID 3 and SEQ ID 4, the method comprising the steps of: a) culturing in large scale mammalian cells that express antigen binding protein in a cell culture production medium, wherein the culturing step effectively maintains the cell count in the range of 10 × 10 6 - 20 × 10 6 cells/ml and results in a yield of at least 2 g/ L wherein the cell line of mammalian cells is CHO-K1 SV GS-KO when the antigen binding protein is an anti-Dengue monoclonal antibody and the cell line of mammalian cells is GS-CHO when the antigen binding protein is an anti-Rabies monoclonal antibody; wherein the culturing step includes use of basal medium, use of concentrated basal medium as feed solution, use of feed solutions along-with a definite feeding strategy, resulting in enhanced cell growth, maintaining lower concentrations of lactate and ammonia, and effectively maintaining the cell count thereby increasing cell longevity and high yield; b) purification of antigen binding protein from harvested supernatant obtained in step (a), wherein the purification results in recovery of at least 80% and purity of at least 99%; and wherein the purification comprises affinity chromatography, Low pH viral inactivation, cation exchange chromatography, anion exchange chromatography, nanofiltration, Tangential flow filtration/Ultrafiltration; in a sequential manner; wherein the affinity chromatography matrix is Protein A; wherein the salt concentration of the buffers used in purification is in the range of 30 mM - 500 mM; and c) preparing a stable formulation comprising the antigen binding protein, wherein osmolality of the formulation is in range of 300 - 400 mOsm/Kg and the viscosity of the formulation is less than 2.5 mPa-S, wherein the formulation comprises at least one antigen binding protein, at least one stabilizer, at least one buffering agent, at least one tonicity agent, and at least one surfactant; wherein the formulation comprises: (i) 1 - 100 mg/ml of the antigen binding protein; (ii) 20 - 40 mM of histidine; (iii) 50 - 100 mM of arginine; (iv) 0.002 - 0.02% Polysorbate 80 (w/v); (v) 50 - 150 mM NaCl; and (vi) 0.1 - 2.5% sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5; and wherein the resulting formulation is stable at 2-8 deg C for at least 9 months, at 25 deg C for at least 1 month, at 40 deg C for at least 40 days, at 50 deg C for at least 2 days. a) culturing in large scale mammalian cells that express antigen binding protein in a cell culture production medium, wherein the culturing step effectively maintains the cell count in the range of 10 × 10 6 - 20 × 10 6 cells/ml and results in a yield of at least 2 g/ L wherein the cell line of mammalian cells is CHO-K1 SV GS-KO when the antigen binding protein is an anti-Dengue monoclonal antibody and the cell line of mammalian cells is GS-CHO when the antigen binding protein is an anti-Rabies monoclonal antibody; wherein the culturing step includes use of basal medium, use of concentrated basal medium as feed solution, use of feed solutions along-with a definite feeding strategy, resulting in enhanced cell growth, maintaining lower concentrations of lactate and ammonia, and effectively maintaining the cell count thereby increasing cell longevity and high yield; b) purification of antigen binding protein from harvested supernatant obtained in step (a), wherein the purification results in recovery of at least 80% and purity of at least 99%; and wherein the purification comprises affinity chromatography, Low pH viral inactivation, cation exchange chromatography, anion exchange chromatography, nanofiltration, Tangential flow filtration/Ultrafiltration; in a sequential manner; wherein the affinity chromatography matrix is Protein A; wherein the salt concentration of the buffers used in purification is in the range of 30 mM - 500 mM; and c) preparing a stable formulation comprising the antigen binding protein, wherein osmolality of the formulation is in range of 300 - 400 mOsm/Kg and the viscosity of the formulation is less than 2.5 mPa-S, wherein the formulation comprises at least one antigen binding protein, at least one stabilizer, at least one buffering agent, at least one tonicity agent, and at least one surfactant; (i) 1 - 100 mg/ml of the antigen binding protein; (ii) 20 - 40 mM of histidine; (iii) 50 - 100 mM of arginine; (iv) 0.002 - 0.02% Polysorbate 80 (w/v); (v) 50 - 150 mM NaCl; and (vi) 0.1 - 2.5% sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5;